{
  "_id": "a90444923d9a07a5cb2daca9dbb7f2cebe7d1cb7d43ab6bc0e001618c6983cdd",
  "feed": "wall-street-journal",
  "title": "Amgen in Advanced Talks to Buy Horizon Therapeutics; The U.S. biotechnology company was the last of three suitors standing in an auction for Horizon",
  "text": "<p>A deal could be finalized by Monday assuming the talks with Amgen don't fall apart, the people said.</p><p>Horizon develops medicines to treat rare autoimmune and severe inflammatory diseases that are currently sold mostly in the U.S. Its biggest drug, Tepezza, is used to treat thyroid eye disease, an affliction characterized by progressive inflammation and damage to tissues around the eyes.</p><p>The company is Nasdaq-listed, but based in Ireland and has operations in Dublin, Deerfield, Ill., and a new facility in Rockville, Md.</p><p>Horizon said last month it was fielding takeover interest from Amgen, Sanofi and Johnson &amp; Johnson, a disclosure prompted by a Wall Street Journal report.</p><p>Johnson &amp; Johnson later said it had dropped out.</p><p>(Updates to follow as news develops.)</p><p>Write to Ben Dummett at ben.dummett@wsj.com, Dana Cimilluca at dana.cimilluca@wsj.com and Laura Cooper at laura.cooper@wsj.com</p><p>Amgen in Advanced Talks to Buy Horizon Therapeutics</p>",
  "published": "2022-12-11T19:11:00.000Z",
  "tags": [
    {
      "id": "US4781601046",
      "nexusId": "10010560",
      "name": "Johnson & Johnson",
      "offsets": [
        {
          "start": 679,
          "end": 696
        },
        {
          "start": 605,
          "end": 622
        }
      ]
    }
  ]
}